Result for
Tag: treatment
March 11, 2021
Convalescent Plasma in Patients Admitted to Hospital with COVID-19 (RECOVERY) a Randomised Controlled Open-Label Platform Trial
[Pre-print, not peer-reviewed] Convalescent plasma (CP) was not associated with improved 28-day survival compared to usual care (RR=1.00, 95% CI: 0.93-1.07) ] in a randomized controlled trial of hospitalized patients (RECOVERY TRIAL). The open-label platform trial (RECOVERY Trial) was conducted between May 2020 to January 2021 in the UK. The mortality risk was similar in…
March 10, 2021
Extremely Potent Human Monoclonal Antibodies from COVID-19 Convalescent Patients
A study that identified highly potent human monoclonal antibodies (mAbs) found that the most potent mAbs recognized the SARS-CoV-2 spike protein receptor-binding domain, followed by those that recognized the S1 domain, the spike protein trimer, and the S2 subunit. Only 1.4% neutralized the virus with a potency of 1–10 ng/mL. The authors also engineered the most…
March 8, 2021
Impact of Remdesivir on 28 Day Mortality in Hospitalized Patients with COVID-19 February 2021 Meta-Analysis
[Pre-print, not peer-reviewed] A meta-analysis of peer-reviewed randomized controlled trials (n = 4 studies, 7,333 patients) did not find differences in survival between patients receiving remdesivir versus usual care or placebo (OR = 0.89, 95% CI 0.65-1.21). Considerable variability in illness severity was noted, with between 0-27% of patients mechanically ventilated at the time of…
March 5, 2021
Sarilumab in Patients Admitted to Hospital with Severe or Critical COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
In a randomized, placebo-controlled, double-blind trial, the IL-6 receptor inhibitor sarilumab did not reduce the median time to improvement by day 29 among patients hospitalized for COVID-19 compared to placebo (n=416). Patients receiving placebo had a median time to improvement of 12 days, compared to 10 days among those receiving either 200 mg or 400…
Tocilizumab plus Standard Care versus Standard Care in Patients in India with Moderate to Severe COVID-19-Associated Cytokine Release Syndrome (COVINTOC): An Open-Label, Multicentre, Randomised, Controlled, Phase 3 Trial
A multi-center, phase-3, randomized trial among patients (n=180) with moderate to severe COVID-19 conducted at 12 hospitals across India of the anti-IL-6 receptor monoclonal antibody treatment tocilizumab found no significant difference in the proportion of patients with progressive COVID-19 up to day 14 between the treatment group compared to standard care group (9% vs 13%)….
Articles Azithromycin for Community Treatment of Suspected COVID-19 in People at Increased Risk of an Adverse Clinical Course in the UK (PRINCIPLE): A Randomised, Controlled, Open-Label, Adaptive Platform Trial
Use of the antibiotic azithromycin plus usual care did not provide meaningful benefits to recovery time from COVID-19 compared to usual care alone, according to a randomized, placebo-controlled, open-label trial in the UK from May to November 2020. Patients receiving azithromycin plus usual care (n=500) had similar time to recovery compared to patients receiving usual…
March 4, 2021
Non-Steroidal Anti-Inflammatory Agent Use May Not Be Associated with Mortality of Coronavirus Disease 19
In a study of patients with COVID-19 using non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen, there was no significant difference in all-cause mortality between the groups (4% vs 3%, HR=1.33, 95% CI: 0.63-2.88) after using propensity score matching to create comparable groups of treated and untreated patients (n=397 data pairs). There were also no significant differences…
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
In a randomized clinical trial among patients with symptomatic, laboratory-confirmed SARS-CoV-2 infection (n=400), a 5-day course of ivermectin did not significantly improve the time to symptom resolution compared with placebo (10 vs 12 days, HR=1.07, 95%CI: 0.87-1.32). Fifteen (7.5%) patients in the ivermectin group versus 5 (2.5%) in the placebo group discontinued treatment due to…
March 2, 2021
A Shorter Symptom-Onset to Remdesivir Treatment (SORT) Interval Is Associated with a Lower Mortality in Moderate-to-Severe COVID-19: A Real-World Analysis
In a retrospective analysis of patients with moderate-to-severe COVID-19 in India (n=346), patients receiving remdesivir 9 days or less after symptom onset had significantly lower all-cause mortality compared to those who received it after 9 days (18% vs 34%). Odds of death were reduced by 37% among patients receiving remdesivir <=9 days post-symptom onset compared…
March 1, 2021
Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19
A meta-analysis of randomized clinical trials comparing patients with COVID-19 treated with convalescent plasma versus control did not detect any significant differences in all-cause mortality, length of hospital stay, mechanical ventilation use, clinical improvement, or clinical deterioration. Results from 4 published, peer-reviewed RCTs including 1,060 patients indicated that the risk ratio for mortality was 0.93….
Previous page Next page